Full-Time

Director of Quality Control

Posted on 8/20/2025

Strand Therapeutics

Strand Therapeutics

51-200 employees

Develops programmable, long-acting mRNA therapeutics

No salary listed

Boston, MA, USA

In Person

Category
Biology & Biotech (3)
, ,
Requirements
  • B.S. or advanced degree in Life Sciences, Chemistry, Biology or similar field.
  • 10-15+ years of QC experience working in biotech, pharma or a similar space required.
  • Extensive QC experience within the gene/cell therapies space and experience with mRNA LNP therapies is required.
  • Exceptional project management skills and proven track record of generating deliverables in a timely manner.
  • Experience with FDA, GMP and regulatory standards required.
  • Knowledge and/or experience in leveraging AI to build efficiencies into QC processes.
  • Experience with health authority inspections is required.
  • Ability to quickly adapt to change and thrive in a dynamic and entrepreneurial early-stage environment.
  • A strong team player with excellent oral and written communication skills and a demonstrated ability to work independently.
Responsibilities
  • Serve as Head of Quality Control and build an internal QC function under the direction of the Vice President of Quality, including resource planning, development of processes and procedures, oversight of all QC-related data, evaluation of computerized system needs and timing related to the development lifecycle.
  • Provide QC leadership and ownership for GMP Stability, Specifications, batch data review, COA generation, OOS investigation, and Reference Standards.
  • Ensure QC readiness for internal and external audits as well as inspections, prepare required documentation, and champion data integrity across systems.
  • Partner with External Contract Labs and Strand Technical Operations (including analytical development, manufacturing and clinical supply chain) to optimize release workflows and minimize deviations.
  • Provide leadership to drive late phase analytical method validation strategies.
  • Manage QC budgetary needs including but not limited to external resources such as consultants, vendor relationships etc.
  • Partner with Quality Assurance Operations and Quality Systems as the QC subject matter expert to ensure cohesiveness amongst systems and workflows.
  • Collaborate with Regulatory Sciences to complement the regulatory strategies for all program needs.
Desired Qualifications
  • Prior experience building an internal QC function and infrastructure preferred.

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company Size

51-200

Company Stage

Series B

Total Funding

$256M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • STX-001 Phase 1 showed confirmed complete response and partial responses by April 2025.
  • $153M Series B from Regeneron, Lilly, Amgen funds STX-003 Phase 1 in 2026.
  • New CFO Kunal Bhatia and CMO Jason Luke strengthen leadership for Phase 2 transition.

What critics are saying

  • Regeneron's liblocalcin achieves 62% ORR in refractory melanoma, eroding STX-001 edge.
  • FDA clinical hold on self-replicating RNA like Gritstone's halts STX-001 by Q2 2026.
  • Eli Lilly enforces milestone repayment if STX-001 misses 20% ORR in Q4 2026 readout.

What makes Strand Therapeutics unique

  • STX-001 deploys programmable mRNA with logic circuits sensing diseased cells only.
  • Intratumoral STX-001 produces localized IL-12, activating immunity without systemic toxicity.
  • Platform enables cell-type specific, multi-functional mRNA therapies for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Phone/Internet Stipend

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-4%
The Pharma Data
Aug 23rd, 2025
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer

Strand Therapeutics strengthens leadership with appointment of Dr. Jason J. Luke as Chief Medical Officer.

BiopharmaTrend
Aug 11th, 2025
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Kinnevik's Ala Alenazi, Ph.D., will join Strand's board of directors.

Crunchbase
Aug 8th, 2025
The Week's 10 Biggest Funding Rounds: Public Safety Leads, While Healthcare And Fintech Also See Big Deals

Strand Therapeutics, $153M, biotechnology: Boston-based Strand Therapeutics, a developer of mRNA-based therapeutics, raised $153 million in a Series B funding led by Kinnevik.

Business Wire
Aug 8th, 2025
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

BioSpace
Aug 7th, 2025
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds

Strand Therapeutics on Thursday closed a $153 million series B round that will help it advance its pipeline of novel mRNA therapies for cancer and other chronic conditions.

INACTIVE